USPTO serial 79298631
UPPLUS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Feb 22, 2022
- Examiner
- RIBAUDO, MICHELLE RACHEL
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with UPPLUS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Nutritionally fortified herbal beverages for medicinal use; Nutritionally fortified medicated beverages; Nutritionally fortified medicinal beverages for medical purposes; Vitamin enriched sparkling water for medical purposes; Nutritionally fortified water for medical purposes; Vitamin enriched water for medical purposes; disinfectants for hygiene purposes; Medicated products for oral hygiene, namely, medicated toothpaste; Medicated mouthwash for oral hygiene purposes; Preparations for oral hygiene, namely, medicated toothpaste, other than dentifrices; Preparations for personal hygiene, namely, disinfectants; Disinfectants for hygienic purposes; Acne treatment preparations in the form of cleansers; Acne treatment preparations in the form of creams; anti-bacterial pharmaceutical preparations; Chemical products for pharmaceutical use for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; Chemicals for pharmaceutical use for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; Pharmaceutical preparations for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; Pharmaceutical preparations for animals for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; Pharmaceutical preparations for application to the skin for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; pharmaceutical preparations for health care for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; pharmaceutical preparations for human use for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; pharmaceutical preparations for nasal use for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; pharmaceutical preparations for oral use for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; pharmaceutical preparations for personal use for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; pharmaceutical preparations for skin care; Pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for topical use for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; pharmaceutical preparations for veterinary use for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; pharmaceutical preparations in the form of emulsions for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; pharmaceutical preparations in the form of throat lozenges and medicated lozenges; pharmaceutical preparations in the form of tablets for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; pharmaceutical products for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; pharmaceutical products derived from natural sources for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; pharmaceutical tonic preparations for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; plant extracts for pharmaceutical purposes; plant extracts for pharmaceutical use; Pharmaceutical preparations in the nature of plant extracts for pharmaceutical use; propolis for pharmaceutical purposes; Drug delivery agents in the form of tablets that facilitate the delivery of pharmaceutical preparations; medicated mouth spray; mouth sprays for medical use; Anti-inflammatory sprays for the body for medical use; sprays for use on the body namely, medicaments for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; Acne treatment sprays for use on the body; medicated mouthwashes; medicated antiseptic mouthwashes; medical mouthwashes; mouthwashes and gargles for medical purposes; mouthwashes for medical purposes; eye drops; throat lozenges for pharmaceutical purposes; medicated throat lozenges; medical toothpastes; medicated toothpaste | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by APEX BIOTECH RESEARCH PTY LTD
- Other trademarks owned by APEX BIOTECH RESEARCH PTY LTD
- Other trademarks owned by APEX BIOTECH RESEARCH PTY LTD
- Other trademarks in Class 005
- Similar marks named UPPLUS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 16, 2022 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jul 27, 2022 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jul 27, 2022 | FIMP | FINAL DISPOSITION PROCESSED | — |
| May 22, 2022 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Feb 22, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 7, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 7, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 6, 2021 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Nov 17, 2021 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Nov 17, 2021 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Nov 17, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 1, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 1, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 1, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 1, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 25, 2021 | RFNT | REFUSAL PROCESSED BY IB | — |
| Apr 5, 2021 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Apr 5, 2021 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 29, 2021 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 28, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 22, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 8, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Dec 2, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 26, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |